An international research consortium led by Dr Jordi Surrallés, director of the Genetics Service at the Hospital de Sant Pau and professor of Genetics at the UAB, and by Dr Miquel Àngel Pujana, director of the ProCURE Research Programme of the Catalan Institute of Oncology (ICO, IDIBELL), has identified a novel gene involved in this...
Tag: <span>Breast Cancer</span>
Post
Drug suppresses spread of breast cancer caused by stem-like cells
A rare-stem like tumor cell, which plays a critical role in the spread of breast cancer, is identified with immunostaining for the β3 integrin subunit (blue) and transcription factor Slug (brown). Rare stem-like tumor cells play a critical role in the spread of breast cancer, but a vulnerability in the pathway that powers them...
Post
Diabetes drug metformin inhibits multidrug-resistant breast cancer
The drug metformin, typically prescribed to treat type 2 diabetes, keeps breast cancer cells from developing multiple drug resistance (MDR) and can reverse MDR after it¹s appeared, according to a study published December 6, 2017 in the open-access journal PLOS ONE by Terra Arnason from the University of Saskatchewan, Canada, and colleagues. Previous studies have shown that...
Post
ECOG-ACRIN discovers a simple blood test may predict recurrence of breast cancer
A proof-of-concept study by the ECOG-ACRIN Cancer Research Group measured circulating tumor cells (CTCs) in blood samples from patients cancer-free five years after diagnosis, then associated CTC presence with a later recurrence ECOG-ACRIN CANCER RESEARCH GROUP A simple blood test that detects tumor cells circulating in the blood shows promise as a new way to...
Post
Over-the-counter supplement found on the High Street reduces breast cancer aggressiveness by up to 80%, breakthrough study finds
NAC, approved for colds, lowers levels of cancer aggressiveness marker MCT4 MCT4 is reduced by 80%, while the aggressive marker Ki67 decreases by 25% Drug contains antioxidants that make tumors release nutrients, stopping growth Low-toxicity treatment as its acceptable side effects have been shown in colds Researchers from the University of Salford analysed 12 breast cancer...
Post
Two breast cancer drugs get NHS approval
Two breast cancer drugs have been recommended for use by the NHS in England. In draft guidance, the National Institute for Health and Care Excellence (NICE) has approved palbociclib (Ibrance) and ribociclib (Kisqali) for patients with advanced breast cancer. The drugs are thought to slow the growth of the disease and delay the need for other treatments. Cancer...
Post
UVA researchers discover a new target for ‘triple-negative’ breast cancer
So-called “triple-negative” breast cancer is a particularly aggressive and difficult-to-treat form. It accounts for only about 10 percent of breast cancer cases, but is responsible for about 25 percent of breast cancer fatalities. Triple-negative breast cancer earns its name because, unlike other breast cancer subtypes, its cells test negative for estrogen and progesterone receptors, as...
Post
Breast cancer recurrence risk lingers years after treatment ends
Daniel F. Hayes, M.D. Even 20 years after a diagnosis, women with a type of breast cancer fueled by estrogen still face a substantial risk of cancer returning or spreading, according to a new analysis from an international team of investigators published in the New England Journal of Medicine. Standard treatment for estrogen receptor-positive, or...
Post
Epigenetic editing reveals surprising insights into early breast cancer development
Micrograph showing a lymph node invaded by ductal breast carcinoma, with extension of the tumour beyond the lymph node. Changing the epigenetic code of a single gene is enough to cause a healthy breast cell to begin a chain reaction and become abnormal, according to research by Queen Mary University of London (QMUL). The...
Post
Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue. Nearly half of all women in the U.S. have dense breast tissue. “Women who have dense breasts...